title: [Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
abstract: In October 1996, a 26-year-old woman was given a diagnosis of acute myeloblastic leukemia, FAB subtype M1. Treatment with combined chemotherapy achieved a complete remission (CR). In May 1997, the patient received an allogenic bone marrow transplant (BMT) from an HLA-identical sibling donor. Cyclosporine (CsA) and short-term methotrexate were given for graft-versus-host disease (GVHD) prophylaxis. Successful engraftment was obtained and signs of acute or chronic GVHD never developed. Five months after BMT, the patient experienced low-grade fever and blurred vision. Retinal examination demonstrated intraretinal hemorrhages, cotton-wool spots, and retinal detachments, which were presumably attributable to multiple thrombosis of retinal microvessels. The patient also exhibited hemolytic anemia with red cell fragmentation, thrombocytopenia, elevated lactate dehydrogenase, and renal impairment, and was thus given a diagnosis of BMT-associated thrombotic microangiopathy (BMT-TM). Discontinuation of CsA and administration of ticlopidine and prednisolone induced successful recovery from BMT-TM. Three months after the onset of BMT-TM, however, the patient experienced generalized clonic-tonic seizures with consciousness loss. Single-photon-emission computed tomography revealed blood-flow disturbances in the brain, suggesting the recurrence of microthrombosis. Accordingly, multiple transfusions of fresh frozen plasma were administered together with dipyridamole and aspirin. The patient gradually recovered and remained asymptomatic through the following 13 months. Currently, early diagnosis of BMT-TM is considered to be difficult. We suggest that careful examination of the ocular base may be useful for the early detection of BMT-TM.
authors.affiliation: First Department of Internal Medicine, Kansai Medical University.
authors.forename: K
authors.initials: K
authors.lastname: Nakai
authors.forename: K
authors.initials: K
authors.lastname: Tajima
authors.forename: Y
authors.initials: Y
authors.lastname: Kishimoto
authors.forename: K
authors.initials: K
authors.lastname: Katsura
authors.forename: M
authors.initials: M
authors.lastname: Kawamura
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Hanada
authors.forename: K
authors.initials: K
authors.lastname: Zen
authors.forename: R
authors.initials: R
authors.lastname: Amakawa
authors.forename: M
authors.initials: M
authors.lastname: Fujimoto
authors.forename: S
authors.initials: S
authors.lastname: Fukuhara
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008833:Microcirculation; D010949:Plasma; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D012171:Retinal Vessels; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome; D014786:Vision Disorders / Q000188:drug therapy / Q000209:etiology*
chemical_list: D004176:Dipyridamole; D011239:Prednisolone; D001241:Aspirin